HIV Part Dos By Alaina Darby.

Slides:



Advertisements
Similar presentations
Case 2: 40-year-old Woman with Long-standing HIV Infection
Advertisements

Principles of care of the HIV-1 infected pregnant mother Protection of mothers from mono- and dual- therapies likely to induce resistance: Women refusing.
IAS–USA Choosing the Initial Antiretroviral Regimen Paul A. Volberding, MD Professor of Medicine University of California San Francisco FINAL:
Prescription and Use of Paediatric Antiretroviral Drugs (ARVs) for the Treatment of HIV in Children.
PROMISE Introduction to PROMISE Protocol May 6, 2009.
WHO Guidelines for treatment monitoring Nathan Ford Dept of HIV/AIDS World Health Organization.
Feedback from Pregnancy research group UK CHIC / UK HIV Drug Resistance Database Meeting, 2 July 2010 Pregnancy Group: Jane Anderson, Loveleen Bansi, Susie.
Presenter : Dr T. G. Nematadzira on behalf of The IMPAACT PROMISE 1077BF/1077FF Team Efficacy and Safety of Two Strategies to Prevent Perinatal HIV Transmission.
Safe Sex & Birth Control Options. Making the decision Difficult decision When is the time right? Are you ready? What steps should you take to protect.
1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Switch to TDF/FTC/RPV  SPIRIT Study. SPIRIT study: Switch PI/r + 2 NRTI to TDF/FTC/RPV TDF/FTC/RPV STR 24 weeks 48 weeks Primary Endpoint Secondary Endpoint.
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
When to Initiate ART in Adults and Adolescents (2009 WHO Guidelines) Target PopulationClinical conditionRecommendation Asymptomatic Individuals (including.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.
IAS–USA Special Considerations: When and What to Start with Viral Hepatitis Coinfections Joseph J. Eron, Jr, MD Professor of Medicine University of North.
CARE OF THE NEONATE. August Infants Born to Mothers with Unknown HIV Infection Status (1) Determine possible HIV exposure and need.
Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.
The Pregnancy Journey Open discussion. HIV and AIDS 2013 Romania Cumulative number people diagnosed with HIV since ,261 (of which 9,946 diagnosed.
Comparison of NNRTI vs PI/r  EFV vs LPV/r vs EFV + LPV/r –A5142 –Mexican Study  NVP vs ATV/r –ARTEN  EFV vs ATV/r –A5202.
Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
ANTEPARTUM CARE. Pregnant Women Who Are ARV Naive (1)  Pregnant women with HIV infection should receive standard clinical, immunologic, and virologic.
SPECIAL CONSIDERATIONS August
Transmission of HIV from mother to fetus. - is not simply one of the major health problems today, but also a big problem in the field of human rights.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
HAIVN Harvard Medical School AIDS Initiative in Vietnam
PMTCT around the world Where are we? PMTCT Experts Roundtable Geneva, June 2008.
Communicating with Patients and Providers HIV Care and ART: A Course for Pharmacists.
MSUCOM OST574 HIV And OB/GYN Peter G. Gulick, DO, FACP, FACOI, FIDSA Associate Professor College of Osteopathic Medicine Michigan State University 1.
WHO 2013 Consultative Meeting Tawanna Hotel October 15, 2013.
IMPAACT 2010 Eligibility Criteria
Maternal Toxicity Management
Switch to PI/r monotherapy
Maternal clinical considerations
GERD Tutoring By Alaina Darby.
HIV Tutoring By Alaina Darby.
More Antibiotics Tutoring
Hepatitis Tutoring By Alaina Darby.
Pharmacokinetics: HIV Drugs
Maternal Toxicity Management
ART 101 Successful HIV treatment usually consists of at least three drugs from two different “classes” of ARV drugs There are now six classes of ARV drugs:
ARV-trial.com Switch to LPV/r + RAL KITE Study 1.
Module 4: Role Playing and Case Discussions
Maternal Toxicity Management
Protocol References Section Title 6.2 Entry Visit 5.1
Pharmacokinetics: HIV Drugs
Better Retention Rates Observed in Patients on Lopinavir than Atazanavir in Uganda
Protocol References Section Title 6.2 Entry Visit 5.1
IMPAACT 2010 Eligibility Criteria
IMPAACT 2010 Eligibility Criteria
What’s New in the Perinatal Guidelines
VL patient support: General education at different levels
The Brazilian Experience
Switch to DTG-containing regimen
Translating Emerging HIV Data Into Clinical Practice
Cepheid Symposium, IAS 23rd July 2018
Cases from the Clinic(ians): Case-based Panel Discussion
Next Generation Capsid Inhibitor: GS–CA1
Switch to LPV/r monotherapy
Switch to DRV/r monotherapy
Comparison of NNRTI vs PI/r
Anthony D Harries Ministry of Health, Malawi
Switch to INSTI + NNRTI Switch to DTG + RPV SWORD Study
Switch to LPV/r monotherapy
ARV-trial.com Switch to ATV/r + RAL HARNESS Study 1.
Diagnosis and Management of HIV-2 in Adults
Rapid Initiation of Antiretroviral Therapy
Purpose of This Guideline
Presentation transcript:

HIV Part Dos By Alaina Darby

WN has a viral load of 2,000 after 24 weeks of therapy and no documented resistance, which of the following would this be considered? Failure Incomplete response Rebound Suppression b

Repeat testing in 3 weeks WN has a viral load of 2,000 after 24 weeks of therapy and no documented resistance. What should not be done as the initial choice? Change regimen Assess adherence Assess DDIs Repeat testing in 3 weeks a

WN has a viral load of 2,000 after 24 weeks of therapy and no documented resistance. Her adherence is reassessed and the regimen restarted, after 4 weeks her viral load is now at 28. What is this considered? Failure Incomplete response Rebound Suppression d

WN has a viral load of 2,000 after 24 weeks of therapy and no documented resistance. Her adherence is reassessed and the regimen restarted, after 4 weeks her viral load is now at 28. In a few weeks it rises to 250. What is this considered? Failure Incomplete response Rebound Suppression c

WN has a viral load of 2,000 after 24 weeks of therapy and no documented resistance. Her adherence is reassessed and the regimen restarted, after 4 weeks her viral load is now at 28. In a few weeks it rises to 250. What should not be done? Resistance testing Confirm levels Confirm adherence Dose adjust d

She should switch to a different OCD KN is a 23 yo WF who has just been diagnosed with HIV. You want to start her on ART. She is currently taking oral contraceptives and wants to stay on the same OCD. What should you tell her? She should switch to a different OCD She should switch to a different form of hormonal contraceptive She can continue her current OCD She should stop taking hormonal contraceptives completely c

Higher concentrations No change in concentration Lower concentrations KN is a 23 yo WF who has just been diagnosed with HIV. You want to start her on ART. She is currently taking oral contraceptives and wants to stay on the same OCD. What effect would you expect to see with her OCD after typical ART regimens? Higher concentrations No change in concentration Lower concentrations c

KN is a 23 yo WF who has just been diagnosed with HIV KN is a 23 yo WF who has just been diagnosed with HIV. You want to start her on ART. She is currently taking oral contraceptives and wants to stay on the same OCD. You decide to start her on TDF/FTC and are trying to decide on the third agent. Which would be best to maintain the activity of her OCD? DRV LPV EVG DTG d

KN is a 23 yo WF who has just been diagnosed with HIV KN is a 23 yo WF who has just been diagnosed with HIV. You want to start her on ART. She is currently taking oral contraceptives and wants to stay on the same OCD. You decide to start her on TDF/FTC and are trying to decide on the third agent. Which agent should definitely be avoided? EFV NVP ATV DRV a

Etonorgestrel implant Depot medroxyprogesterone Nuvaring KN is a 23 yo WF who has just been diagnosed with HIV. You want to start her on ART. If you were to change her hormonal contraceptive, which would you choose? Etonorgestrel implant Depot medroxyprogesterone Nuvaring Desogestrel and ethinyl estradiol combo b

OB is a 32 yo AAF who was just confirmed to be HIV positive due to prenatal bloodwork. She is 8 weeks pregnant and you want to start her on ART. Which regimen should be avoided? ABC/3TC + EFV ABC/3TC + RPV TDF/FTC + DRV TDF/FTC + ATV a

OB is a 32 yo AAF who was just confirmed to be HIV positive due to prenatal bloodwork. She is 8 weeks pregnant and you want to start her on ART. What should you choose? ABC/3TC + ATV/r ABC/3TC + LPV/r TDF/FTC + ATV/r TDF/FTC + LPV/r a

OB is a 32 yo AAF who was just confirmed to be HIV positive due to prenatal bloodwork. She is 8 weeks pregnant and you want to start her on ART. What should you choose if you were concerned about her kidney function and blood sugar? ABC/3TC + ATV/r ABC/3TC + LPV/r ABC/3TC + RAL ABC/3TC + DTG c

OB is a 32 yo AAF who was just confirmed to be HIV positive due to prenatal bloodwork. She is 8 weeks pregnant and you want to start her on ART. You start her on ABC/3TC + RAL. Treatment for which of the following pregnancy related conditions could be a problem? Depression GERD Diabetes Frequent urination b… don’t take RAL with antacids

RH is 32 weeks pregnant with HIV RNA of 1,200. What should you do? Reevaluate her in 6 weeks and start ZDV now Schedule C-section for 6 weeks and start ZDV now Reevaluate her in 6 weeks and start ZDV at that time if HIV RNA is still high Schedule C-section for 6 weeks and start ZDV at that time d

RH is 38 weeks pregnant now and has come in for her C-section RH is 38 weeks pregnant now and has come in for her C-section. When should you start ZDV? 1 hour prior 2 hours prior 3 hours prior 4 hours prior d

RH is 32 weeks pregnant with HIV RNA of 850. What should you do? Wait until she goes into labor to start ZDV Schedule C-section for 6 weeks with ZDV Wait until she goes into labor and don’t start ZDV Schedule C-section for 6 weeks without ZDV c

When should an infant receive ZDV? All infants born to HIV positive mothers Infants born to HIV positive mothers through natural birth Infants born to HIV positive mothers through C-section Don’t give it! It’s dangerous! a

How long should ZDV continue? 2 weeks 4 weeks 6 weeks 8 weeks

When should an infant receive ZDV + NVP? All infants born to HIV positive mothers Infants born to HIV positive mothers through natural birth Infants born to HIV positive mothers through C-section Infants born to HIV positive mothers not on ART during pregnancy d

How many doses of NVP should the infant get? 3 doses, all within the first week 3 doses, spread across 6 weeks 6 doses, all within the first week 6 doses, spread across 6 weeks a

Remember… Give the kid “zid” so he “nevir” gets HIV!! a

Which of the following is not true of patients over 50? ART may produce more ADRs DDIs with ART are more common Response to ART is reduced ART is not recommend due to risk of ADRs d

Entecavir + fully suppressive ART PA is a 44 yo Wm with HBV. Which of the following regimens is preferred? TDF/3TC + EFV ABC/3TC + RPV ABC/FTC + DRV Entecavir + fully suppressive ART a

TD is HIV positive on ART and was just diagnosed with TB TD is HIV positive on ART and was just diagnosed with TB. His CD4 is 175. For which of the following should he receive prophylaxis? Histoplasmosis MAC PJP CMV c

TD is HIV positive on ART and was just diagnosed with TB TD is HIV positive on ART and was just diagnosed with TB. His CD4 is 175. What should he receive to prophylax against PJP? Pyrmethamine Bactrim Azithromycin Flucomazole b

TD is HIV positive on ART and was just diagnosed with TB TD is HIV positive on ART and was just diagnosed with TB. His CD4 is 175. How long should his prophylaxis extend? 1 year For life Until CD4 >200 Until CD4 >400 c

For which of the following is prophylaxis not recommended? Histoplasmosis MAC PJP CMV d

Which of the following is not acceptable prophylaxis for Toxoplasmosis encephalitis? Bactrim DS Q day Bactrim DS TIW Bactrim SS Q day c

Which of the following is the regimen to prophylax against MAC? Rifabutin Ciprofloxacin Ethambutol Azithromycin d

When can prophylaxis be stopped for MAC? CD4 >50 CD4 >100 After 3 months After 6 months a & c a & d b & c b & d g

When can treatment be stopped for MAC? CD4 >50 CD4 >100 After 3 months After 6 months a & c a & d b & c b & d h